Detection of p53 gene mutations in tumour cells is of great clinical interest because p53 mutations have been shown to be closely related to chemotherapy resistance and poor prognosis.l-' However, in routine practice there is no efficient or convenient method to detect the mutations. Although many investigators use single-strand conformation polymorphism (SSCP) analysis of polymerase chain reaction (PCR) products followed by direct sequencing, the SSCP method is not practical because of several limitations: specimens with more than about 200 bp fragment size cannot be assayed; it is difficult to standardize the electrophoretic conditions such as temperature and compositions of gel and buffer; and the sensitivity is uncertain (up to 90%) and largely dependent on the conditions.v' Cleavase fragment length polymorphism (CFLP) is, like SSCP, primarily a method for detecting mutation-induced changes in secondary structure of single-stranded (ss) DNA, but has additional benefits: it is applicable for fragments up to 2 kb size; specific and reproducible patterns can be obtained; and it is able to detect abnormal signals indicative of mutation site. The endonuclease cleavase 1 5 recognizes and cleaves the 5' side of hairpin loops in selfannealed ssDNA derived from PCR products labelled at the 5' end, and generates end-labelled fragments of various sizes. Electrophoresis of the fragments reveals a sequence-specific CFLP pattern on polyacrylamide gels containing urea. We applied this method to detect mutations in the p53 gene after amplification of its full translational seq uence by reverse transcription (RT)-PCR.
We obtained test samples from bone marrow aspirates from three patients with haematological disorders (two with acute myeloblastic leukaemia and one without malignancy) and
Correspondence: Yasuyuki Okamoto, MD. E-mail: yasuyuki(a.nmu-gw.cc.naramed-u.ac.jp from two cell lines in culture -the human hepatoma cells PLCjPRF/5, known to have a p53 mutation at codon 249 (G:C-> T:A), 6 and HepG2 cells known to have no mutation in the p53 gene. Total RNAs were extracted by the acid guanidinium-phenol--ehloroform method, and converted to cDNA with a StrataScriptw RT-PCR kit (Stratagene Cloning systems, La Jolla CA, USA) using oligo-dT primers. The full translational sequence of the p53 gene was amplified by nested PCR using sense, antisense, internal sense and internal antisense primers 5'-GCTGGGAGCGTGCTTTCCAC-3', 5'-AGA-TGGGGGTGGGAGGCTGT-3', 5'-GGGAG-GCTGTCAGTGGGGAA-3', and 5'-ACGCT-TCCCTGGATTGGCAG-3', respectively. Only the antisense primer for the second PCR was labelled at the 5' end with biotin. The first and second rounds of PCR were performed for 35 cycles (denaturation for 30s at 94°C, annealing for 30 s at 60°C for the first PCR and 52°C for the second, and extension for 90 s at n°C). The second products (1263 bp) were separated on a 2% agarose gel and purified with a GENE-CLEAN II kit (BID 101 Inc, La Jolla CA, USA) from the excised gel for CFLP analysis. These procedures, such as nested PCR and final purification, are necessary for this highly sensitive assay to avoid nonspecific results.
CFLP POWER SCAN@) System, including Cleavase I [25 unitsjul, in 20mmol/L Tris-HCI, pH 8,0, 50mmol/L KCI, 0·5% Tween 20, 0·5% NP-40, 100/lg/mL bovine serum albumin (BSA), and 50% glycerol], buffer concentrate [100 mmol/L 3-(N-morpholino)propanesulphonic acid (MOPS), pH 7'5, 0·5% Tween 20 and NP-40] and the stop solution (95% formamide, 10 mmol/L ethylenediamine tetra-acetic acid, pH 8'0, 0·05% xylene cyanol and 0·05% bromphenol blue) were purchased from Life Technologies Inc, Gaithersburg, Maryland, USA. Denaturation of PCR products was performed for 20 s at 95°C, followed by cleavage for 2 min at 55°C. The reaction was terminated by the Okamoto and Nakano addition of the stop solution. After separation on precast 6% polyacrylamide sequencing gels containing 7 mmol/L urea (CastAwayS Precast Sequencing System, Stratagene Cloning Systems). samples were transferred onto Hybond S N + membranes (Amersham International pic, Amersham, UK). and signals were developed on X-ray film by the chemiluminescence method using streptavidin-alkaline phosphatase complex.
For sequencing the region including exon 7, primers for PCR were designed as 5'-TAGTGT-GGTGGTGCCCTATG-3' and 5'-GCTGTTC-CGTCCCAGTAGAT-3'. PCR was performed for 35 cycles (denaturation for 30s at 94°C, annealing for 30s at 57°C, and extension for 90s at n°C). Sequencing of PCR products was performed using a non-radioisotopic DNA sequencing kit (Sequencing high-Plus-, TOYO-80. Ltd. Osaka. Japan). Separation of DNA fragments and signal detection were performed by the same methods as used for CFLP analysis.
As shown in Fig. la , the most frequent CFLP pattern, indicative of the wild-type sequence, was found in a patient without malignancy, a leukaemic patient and in HepG2 cells. Additional signals were found in a patient with acute myeloblastic leukaemia and PLC/PRF/5 cells, which are known to have a point mutation at codon 249 in exon 7 of the p53 gene. The molecular sizes of these additional signals suggested that the mutations were in exon 7 in both the patient and PLC/PRF/5 cells, because the labelled fragments cleaved in the region corresponding to exon 7 ranged from 437 bp to 546 bp in size. PLC/PRF/5 cells showed a few other additional signals suggestive of the unidentified mutations, possibly in exon 8. We amplified the region including exon 7 of the p53 gene from the patient by PCR using the first PCR products obtained for CFLP analysis and sequenced. Exon 7 showed normal as well as mutated sequences concomitantly. A mutation was found at codon 228 (C:G---> T:A) ( Fig. I b) , but did not cause an amino acid substitution.
We conclude that RT-PCR-based CFLP analysis may be a useful method for screening p53 gene mutations, and that further studies will be needed to confirm this.
